NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Niagen Bioscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$2.50+0.01 (+0.40%)
Close on Oct 19, 2026
- Market cap
- $206.26M
- P/E (TTM)
- 13.9
- Dividend yield
- –
Niagen Bioscience, Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumer Products segment | $24.16M | $22.41M | $27.46M | $26.02M | $22.70M | $21.50M | $22.65M | $18.12M | $18.65M | $17.35M | $17.60M | $17.40M | 81.1% | +6.4% |
| Ingredients segment | $5.39M | $8.56M | $5.69M | $7.20M | $7.62M | $8.17M | $5.75M | $6.67M | $3.30M | $4.09M | $2.89M | $1.42M | 18.1% | -29.3% |
| Corporate and other | $236.00K | $74.00K | – | – | – | – | – | – | – | – | – | – | 0.8% | – |
| Analytical Reference Standards and Services segment | $0 | $423.00K | $694.00K | $772.00K | $799.00K | $811.00K | $722.00K | $784.00K | $791.00K | $714.00K | $707.00K | $671.00K | 0.0% | -100.0% |
| Pharmaceuticals segment | $0 | $0 | – | – | $0 | $0 | – | – | – | – | – | – | 0.0% | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumer Products segment | $5.57M | $4.64M | $9.75M | $7.42M | $6.28M | $5.51M | $6.53M | $3.79M | $3.95M | $2.91M | $3.83M | $4.30M | -11.3% |
| Ingredients segment | $2.60M | $4.54M | $3.94M | $3.80M | $4.46M | $4.75M | $3.45M | $4.10M | $1.51M | $1.84M | $1.58M | $586.00K | -41.6% |
| Analytical Reference Standards and Services segment | $0 | $71.00K | $108.00K | $138.00K | $88.00K | $62.00K | -$52.00K | $12.00K | -$51.00K | -$124.00K | -$146.00K | -$193.00K | -100.0% |
| Pharmaceuticals segment | -$481.00K | -$468.00K | – | – | -$372.00K | -$368.00K | – | – | – | – | – | – | +29.3% |
By product or service
By region
From the segment and revenue-disaggregation notes of Niagen Bioscience's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.